Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 14/20 | 0.58 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | CDK4 | P11802 | 1/20 | 0.44 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | SYK | P43405 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3985388 | 0.90 | CDK1 (0.57) | CDK1GSK3BCHEK1NTRK2CDK2 | |
| SCHEMBL3982426 | 0.86 | CDK1 (0.57) | CDK1GSK3BCHEK1NTRK2CDK2 | |
| SCHEMBL3985391 | 0.83 | CDK1 (0.57) | CDK1GSK3BCHEK1NTRK2CDK2 | |
| SCHEMBL3984442 | 0.75 | CDK1 (0.71) | CDK1CDK2KDR | |
| SCHEMBL3982310 | 0.74 | KDR (0.72) | CDK1CDK2KDR | |
| SCHEMBL15389069 | 0.71 | CDK1 (0.67) | CDK1CDK2CDK4MAPK3SYK | |
| SCHEMBL3984145 | 0.71 | CDK1 (0.60) | CDK1CDK4MAPK3EGFR | |
| SCHEMBL3988091 | 0.69 | CDK1 (0.71) | CDK1CDK2KDRCDK4 | |
| SCHEMBL3983313 | 0.69 | CDK1 (0.61) | CDK1CDK2KDR | |
| SCHEMBL6212019 | 0.68 | PTK2 (0.61) | CDK1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2059511-A1 | SULPHOXIMIDES AS PROTEIN KINASE INHIBITORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-05-20 | — | — | EP | disclosed |
| US-20080167330-A1 | Carbamoylsulphoximides as protein kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2008-07-10 | — | — | US | disclosed |
| US-20080167330-A1 | Carbamoylsulphoximides as protein kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2008-07-10 | — | — | US | disclosed |
| US-20080167330-A1 | Carbamoylsulphoximides as protein kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2008-07-10 | — | — | US | disclosed |
| WO-2008025556-A1 | SULPHOXIMIDES AS PROTEIN KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167330-A1 | Carbamoylsulphoximides as protein kinase inhibitors | CABLES1, CKS2, CDK2AP1 | CDK1 6/4885GSK3B 1143/4885CHEK1 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.